Effects of antiretroviral therapy on pregnancy outcomes for hepatitis B patients

doi:10.3877/cma.j.issn.2095-3259.2014.03.003

Abstract

Abstract:

Antiretroviral therapy for hepatitis B virus carrier during pregnancy may not only cure the disease, but also interrupt intrauterine transmission of hepatitis B virus. The patients during pregnancy should be emphasized, on the basis of maternal serum viral loads and severity of the liver disease, optimal antiviral therapy time and antiviral agents are chosen to achieve favorable pregnancy outcome.

Key words: Hepatitis B, Antiviral agents, Disease transmission, vertical

Qian Huang, Huishu Liu. Effects of antiretroviral therapy on pregnancy outcomes for hepatitis B patients[J]. Chinese Journal of Obstetric Emergency(Electronic Edition), 2014, 03(03): 163-167.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhckjjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3259.2014.03.003

https://zhckjjdzzz.cma-cmc.com.cn/EN/Y2014/V03/I03/163

References 31

[1]	WHO Publication. Hepatitis B vaccines: WHO position paper--recommendations[J]. Vaccine, 2010, 28(3):589-590.
[2]	Gentile I, Borgia G. Vertical transmission of hepatitis B virus: challenges and solutions[J]. Int J Womens Health, 2014, 10(6):605-611.
[3]	中华医学会传染病寄虫学会. 病毒性肝炎防治方案[J]. 中华传染病杂志，1995, 13(4):241.
[4]	Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease [J]. N Engl J Med, 2004, 351(15):1521-1531.
[5]	马军，段芳龄. 亚洲太平洋地区慢性乙型肝炎处理的共识(2005年最新报告)[J]. 胃肠病学和肝病学杂志，2005, 14(5):436-439.
[6]	中华医学会肝病学分会、感染病学分会. 慢性乙型肝炎防治指南[J]. 中华肝脏病杂志，2005, 13(12):881-891.
[7]	Leung N. Chronic hepatitis B in Asian women of childbearing age[J]. Hepatol Int, 2009, 3 Suppl 1:24-31.
[8]	Hu Y, Ding YL, Yu L. The impact of intrahepatic cholestasis of pregnancy with hepatitis B virus infection on perinatal outcomes[J]. Ther Clin Risk Manag, 2014, 23(10):381-385.
[9]	Jonas MM. Hepatitis B and pregnancy: an underestimated issue[J]. Liver Int. 2009, 29 Suppl 1:133-139.
[10]	Sinha S, Kumar M. Pregnancy and chronic hepatitis B virus infection[J]. Hepatol Res, 2010, 40(1):31-48.
[11]	Tse KY, Ho LF, Lao T. The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study[J]. J Hepatol, 2005, 43(5):771-775.
[12]	Giles ML, Audsley J, Lewin SR, et al. Kucers′ the use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs[M]. 6th ed. London: Hodder Arnold, 2010：2545-2562.
[13]	Mandelbrot L, Peytavin G, Firtion G, et al. Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women[J]. Am J Obstet Gynecol, 2001, 184(2):153-158.
[14]	But DY, Yuen M, Fung J, et al. Safety evaluation of telbivudine[J]. Expert Opin Drug Saf, 2010, 9(5):821-829.
[15]	Bridges EG, Selden JR, Luo S. Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B[J]. Antimicrob Agents Chemother, 2008, 52(7):2521-258.
[16]	European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection[J]. J Hepatol, 2012, 57(1):167-185.
[17]	张丽菊，王玲. 替比夫定对妊娠后期乙型肝炎病毒宫内感染的阻断作用[J]. 中华肝脏病杂志，2009, 17(8):561-563.
[18]	韩国荣，江红秀，王根菊，等. 替比夫定对乙型肝炎病毒高载量孕妇母婴传播的阻断效果及其安全性[J]. 中华肝脏病杂志，2012, 3, 20(3):201-205.
[19]	Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection[J]. J Hepatol, 2011, 55(6):1215-1221.
[20]	Kim HY, Choi JY, Park CH, et al. Outcome after discontinuing antiviral agents during pregnancy in women infected with hepatitis B virus[J]. J Clin Virol, 2013, 56(4):299-305.
[21]	Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B[J]. Clin Gastroenterol Hepatol, 2007, 5(8):890-897.
[22]	曹彦君，方芳，刘敏，等. 接受抗病毒治疗的乙型肝炎患者妊娠期耐药20例分析[J]. 药物不良反应杂志，2013, 15(2):69-72.
[23]	Shi Z, Yang Y, Ma L, et al. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis [J]. Obstet Gynecol, 2010, 116(1): 147-159.
[24]	van Zonneveld M, van Nunen AB, Niesters HG, et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection [J]. J Viral Hepat, 2003, 10(4):294-297.
[25]	Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study[J]. J Viral Hepat, 2009, 16(2):94-103.
[26]	Celen MK, Mert D, Ay M, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection[J]. World J Gastroenterol, 2013, 19(48):9377-9382.
[27]	Greenup AJ, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus[J]. J Hepatol, 2014, 61(3):502-507
[28]	Yi W, Liu M, Cai HD. Safety of lamivudine treatment for chronic hepatitis B in early pregnancy[J]. World J Gastroenterol, 2012, 18(45):6645-6650.
[29]	Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B[J]. Hepatology, 2009, 49(5 Suppl):S185-S195.
[30]	中华医学会肝病学分会，中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版) [J]. 中华肝脏病杂志，2011, 19(1):13-24.
[31]	亚太肝病学会慢性乙型肝炎治疗共识工作组. 亚太地区慢性乙型肝炎治疗共识(2012最新版) [J]. 临床肝胆病杂志，2012, 28(8):1-21.

Please choose a citation manager

Content to export